Indian scientists working on developing mRNA vaccine technology get grant

The grant will be for three years and will fund research to develop the platform technologies for mRNA vaccine development

Vials, Vaccine
Photo: Shutterstock
Press Trust of India Bengaluru
2 min read Last Updated : Jul 05 2021 | 2:10 PM IST

Ignite Life Science Foundation has awarded its first grant award for "pandemic preparedness" research to a team of researchers at the Indian Institute of Science (Bengaluru) and the Translational Health Science and Technology Institute (Faridabad).

The team comprises Professor Raghavan Varadarajan, Dr. Mrinmoy De and Dr. SiddharthJhunjhunwala (IISc), and Dr. Amit Awasthi (Translational Health Science and Technology Institute-Faridabad).

The grant, the amount of which was not disclosed, will support the research by them for developing for the first time in India the technologyplatform and reagents required to design, make and test novel mRNA vaccines, ILSF said.

"We hope their work will form the basis for India's ability to respond quickly to future pandemics, as well as improve our ability to respond to new variants of SARS-CoV-2," it said.

"The grant will be for three years and will fund research to develop the platform technologies for mRNA vaccine development," a statement from ILSF,founded by professional scientists, academics and entrepreneurs, said on Monday.

According to Professor Shahid Jameel (Member

Scientific Advisory Board, ILSF),mRNA vaccine development technology is vital for India to mount a rapid and effective response to future pandemics, and successful execution on this project will seed the creation of much needed capabilities in mRNA vaccine development in India.

"The investigators will not only work on developing a vaccine against new variants of SARS-Cov2, but also attempt to develop methods for the generation of thermostable RNA vaccines, which would be critical for resource-poor tropical regions of the world," he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :VaccineHealthcare sectorIISc

First Published: Jul 05 2021 | 2:09 PM IST

Next Story